Journal article
Acute myelogenous leukemia in adolescents and young adults
Abstract
The incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50-60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic …
Authors
Creutzig U; Kutny MA; Barr R; Schlenk RF; Ribeiro RC
Journal
Pediatric Blood & Cancer, Vol. 65, No. 9,
Publisher
Wiley
Publication Date
September 2018
DOI
10.1002/pbc.27089
ISSN
1545-5009
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Abnormal KaryotypeAdolescentAdultAge of OnsetAntineoplastic Combined Chemotherapy ProtocolsCell DifferentiationChildChild, PreschoolClinical Trials as TopicEuropeFemaleHematopoietic Stem Cell TransplantationHumansIncidenceInfantInfertilityLeukemia, Myeloid, AcuteMaleMiddle AgedMulticenter Studies as TopicNeoplasms, Second PrimaryPatient SelectionPrognosisSurvival AnalysisUnited StatesYoung Adult